• Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030
  
  
• Enables manufacturing of medicines across company’s main therapeutic areas in one geographic location
  
  
• Marks latest milestone in company’s previously announced $23 billion investment in US infrastructure
  

East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end manufacturing capabilities. The strategic investment is a major step to ensure all key Novartis medicines for US patients are manufactured in the US and delivered to patients across the country at scale.

This announcement is part of Novartis’ $23 billion investment in US-based infrastructure over the next five years, designed to increase manufacturing capacity and enable 100% of the company's key medicines to be produced end-to-end in the US.

As part of this flagship hub in North Carolina, Novartis will:

• Build a new site in Durham with the construction of two new facilities dedicated to manufacturing biologics and sterile packaging
• Build a new site in Morrisville with one facility for the production of solid dosage tablets and capsules, including packaging
• Expand the scope of its existing Durham facility with the added capability to support sterile filling of biologics into syringes and vials
  

The company is on track to produce all its advanced technologies in the US with:

• Cell and gene therapies manufactured in Morris Plains, NJ, and Durham, NC
• Radioligand therapies manufactured coast-to-coast at facilities in Millburn, NJ, Indianapolis, IN, and Carlsbad, CA, and two new sites planned in Florida and Texas
• xRNA therapies to be manufactured at a new facility whose location will be announced in the coming months
  

Currently, Novartis produces innovative, life-changing gene therapies in Durham. Together, the new and existing facilities will create a single hub, expanding capabilities to produce medicines across the company’s main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic. The proximity of the facilities will allow teams and production processes to work in tandem – from manufacturing active ingredients to final packaging – and create efficiencies in its manufacturing.

“This announcement is a commitment to American innovation and to the patients we serve,” said Vas Narasimhan, CEO of Novartis. “By building a full, end-to-end manufacturing presence in North Carolina for our broader portfolio, we are expanding our capacity to deliver medical breakthroughs, securing a more resilient US supply chain, and investing in the local communities that make our mission possible.”

“North Carolina continues to lead in advanced pharmaceutical manufacturing, and Novartis’ expansion in the Triangle reflects our state’s talent and innovative spirit,” said Governor Josh Stein. “This investment will strengthen our state’s economy and ensure life-saving medicines continue to be made right in North Carolina.”

Anticipated to open in 2027-2028, the flagship manufacturing hub, encompassing more than 700,000 square feet between the existing campus and new facilities, is expected to create 700 new jobs at Novartis and more than 3,000 indirect jobs across the supply chain by the end of 2030.

This latest expansion builds on the existing Novartis presence – creating skilled jobs, fueling workforce growth, supporting local communities, and solidifying North Carolina’s strength in pharmaceutical manufacturing.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram.

# # #